Investment research house Edison Group has set a valuation of A$66.7 million (6.1 cents per share) for Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF), framing the company’s reset around anti-VISTA checkpoint candidate HMBD-002 as the key to a potential re-rating.
With Percheron’s cash position of A$10.2 million and full Phase I data due later in the year ahead of Phase II in 2026, Edison analysts Jyoti Prakash and Arron Aatkar see a defined catalyst path — albeit with the execution and target-validation risks typical of early clinical programmes.
Why VISTA — and HMBD-002 — matter
HMBD-002, acquired under a global licence from Hummingbird Biosciences in June 2025, is designed to inhibit VISTA, an immune brake implicated in resistance to PD-1/PD-L1 therapy. Edison noted that VISTA appears upregulated in a meaningful subset of tumours and across myeloid-lineage cells in the tumour micro-environment — making it a compelling next-generation checkpoint for combination regimens.
Crucially, HMBD-002 uses an IgG4 backbone (most rival anti-VISTA programmes are IgG1), which is intended to block VISTA’s immunosuppressive function without depleting VISTA-expressing cells. That design aims to reduce the risk of cytokine release syndrome seen in earlier attempts to drug the target and could enable higher, sustained dosing.
In a completed US Phase I study (monotherapy and in combination with Keytruda®), HMBD-002 was generally safe and pharmacologically active; full data are expected in the fourth calendar quarter of 2025. Percheron plans to start Phase II trials in 2026.
Catalysts, scope and market context
While detailed Phase II designs are yet to be disclosed, Edison thinks the highest-probability path is combination therapy with pembrolizumab (Keytruda) across multiple solid tumours such as non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and melanoma.
The analysts cited the expanding immune checkpoint inhibitor (ICI) market — estimated at US$50 billion in 2023 and projected to US$150 billion by 2030 — as a key backdrop; even modest share capture could translate into significant revenue if efficacy is shown.
Edison highlights a series of near-term milestones likely to shape sentiment around Percheron:
- Full Phase I dataset for HMBD-002 in Q4 CY25.
- Disclosure of Phase II design and indications in Q4 CY25.
- Phase II initiation in CY26, with initial sites and combination strategy detail.
Valuation and assumptions
Edison’s A$66.7 million, 6.1-cents-per-share base-case valuation uses a risk-adjusted net present value (NPV) approach anchored to three combination indications (NSCLC, HNSCC, melanoma), a 10% probability of success and an out-licensing scenario before Phase III in 2029. The model assumes:
- Phase II costs of ~US$15 million per indication (~US$45 million total) across staged IIa/IIb studies;
- Effective US pricing of ~US$90,000 per patient per year for HMBD-002, benchmarked at a discount to approved PD-1s;
- Global peak sales potential of ~US$3 billion by 2045 under broader label expansion, with 12 years’ US market exclusivity typical of novel biologics.
A peer sense-check suggests upside versus Percheron’s current market capitalisation (which Edison notes is below cash), while a comparison to ASX immuno-oncology peer Immutep illustrates how value can accrete through successive clinical milestones in checkpoint programs.
Funding position and deal terms
Percheron’s pivot was enabled by the HMBD-002 licence from Hummingbird: US$3 million upfront (US$2 million paid; US$1 million due on delivery of initial drug substance), up to US$287 million in milestones and tiered royalties starting at 12.5%.
Edison forecasts higher research and development (R&D) spend from FY26 as Phase II commences and estimates an additional ~A$40 million of capital required before the anticipated out-licence in FY29. Australia’s R&D tax incentive remains an important non-dilutive offset.
Sensitivities and execution risks
Edison emphasised the usual binary risks for clinical-stage biotechs, heightened here by single-asset concentration and the relative novelty of VISTA in human studies. Key sensitivities include:
- Clinical execution: final Phase II design, dose optimisation and patient selection (including potential biomarker strategies) to establish proof-of-concept.
- Target validation and safety: confirming that IgG4-based, non-depleting VISTA blockade can deliver efficacy without immune-related toxicities that limit dosing.
- Financing: additional equity likely ahead of out-licensing; terms could be shaped by collaboration structures (e.g., access to PD-1 supply) and trial geography.
- Competition/partnering: HMBD-002 must differentiate versus other next-gen ICIs and combination approaches; attractive royalty economics (≥20% in Edison’s framework) will be important given the 12.5% pay-away.
The bottom line
Edison’s initiation of coverage frames Percheron as a reset story now anchored to a mechanistically differentiated checkpoint with combination potential in large tumour settings.
With full Phase I data and Phase II blueprints due in Q4 CY25 and first efficacy studies slated for CY26, the next 12–18 months set the stage for decisive read-throughs on HMBD-002’s clinical and partnering trajectory — and, by extension, Percheron’s valuation path.